Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Total Liabilities (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Total Liabilities data on record, last reported at $214.0 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 95.22% year-over-year to $214.0 million; the TTM value through Sep 2025 reached $214.0 million, up 95.22%, while the annual FY2024 figure was $215.8 million, 73.32% up from the prior year.
  • Total Liabilities reached $214.0 million in Q3 2025 per GLUE's latest filing, up from $91.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $215.8 million in Q4 2024 and bottomed at $65.0 million in Q2 2023.
  • Average Total Liabilities over 3 years is $118.6 million, with a median of $114.2 million recorded in 2024.
  • The widest YoY moves for Total Liabilities: up 95.22% in 2025, down 23.39% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $124.5 million in 2023, then surged by 73.32% to $215.8 million in 2024, then dropped by 0.83% to $214.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $214.0 million in Q3 2025, $91.5 million in Q2 2025, and $118.0 million in Q1 2025.